Just a matter of time Even fully diluted at 325 million, assuming warrants and options exercised, at 1$ a share, is it that hard to value Theralase at 300 million?
The bladder treatment could net them several hundred million in revenue.
But it's the value of Rutherrin to Big Pharma.
Lung cancer, brain cancer, pancreatic cancer, Herpes.... what else has been mentioned?